Ask AI
ProCE Banner Activity

BCT1902/IBCSG 61-20 Neo-N: Phase II Trial of Concurrent Nivolumab Plus Neoadjuvant Chemotherapy With and Without Lead-In Nivolumab in Stage I/II TNBC

Conference Coverage
Slideset

Phase II Neo-N trial data suggest that a 12-week regimen of nivolumab plus neoadjuvant chemotherapy with or without a nivolumab lead-in, followed by surgery, leads to high pCR rates in patients with stage I/II triple negative breast cancer.

Released: December 10, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.